using machine learning to identify trajectories of hematotoxicity following car t-cell therapy
Published 7 months ago • 85 plays • Length 3:14Download video MP4
Download video MP3
Similar videos
-
0:59
identifying molecular markers for the prediction of icaht in patients receiving car t-cell therapy
-
0:37
factors to consider when managing patients with all prior to car t-cell therapy
-
3:47
update on the guidelines for the diagnosis, grading & management of icaht following car-t therapy
-
1:33
patient selection for car-t in all
-
1:17
diagnosing rt and identifying patients at risk using ngs and molecular cytogenetic analysis
-
1:45
using frailty to determine car-t eligibility in patients with r/r multiple myeloma
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
3:25
identifying & monitoring patients with high-risk clonal hematopoiesis
-
1:14
components of the car-hematotox model which allow for prediction of icaht following car-t
-
2:34
safety considerations in car-t therapy: patient selection and side effects
-
3:07
the role of bridging and timing in car-t
-
1:16
car-t treatment journey and the role of the nurse
-
8:57
outcomes of sct in t-all and t-lbl
-
4:28
car t-cell therapies: selecting patients & associated challenges
-
3:33
determining the optimal sequencing of bispecifics and car-t cells in patients with myeloma
-
1:35
key mechanisms of resistance to car t-cell therapy
-
4:10
car t-cell therapy for all
-
1:52
perspectives on patient selection for car-t therapy